美国 · 平台与数据 · The Motley Fool
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.

详细摘要
Bristol Myers Squibb is facing down the expiration of patent protections for older drugs, but new drugs are starting to show promise.
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.fool.com)



